Handelsavisen
prelaunch
Companies ›Healthcare ›SER
SE
SER — NYSE Pharmaceuticals & Medical Research

Serina Therapeutics, Inc.

$2,06
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
24,8M USD
P/E
—
EV / Rev
-14,9x
Div yield
—
Op margin
—
ROE
-39,1 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$1,95
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Serina Therapeutics, Inc. is a biopharmaceutical company focused on the development of therapeutics for age-related diseases, primarily through its research in senescence and regenerative medicine.

Business. Serina Therapeutics, Inc. (NYSE: SER) is a pharmaceutical company operating within the healthcare sector. The firm focuses on the development and potential commercialization of therapeutic products, with its business activities centered on pharmaceutical research and development. Specific operating segments and geographic breakdowns are not disclosed in the available data. The company is primarily listed on the New York Stock Exchange under the ticker symbol SER.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target13,00

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
13,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership
—
not yet wired
Profitability→
-39,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SER.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SER. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Serina Therapeutics, Inc. (NYSE: SER) is a pharmaceutical company operating within the healthcare sector. The firm focuses on the development and potential commercialization of therapeutic products, with its business activities centered on pharmaceutical research and development. Specific operating segments and geographic breakdowns are not disclosed in the available data. The company is primarily listed on the New York Stock Exchange under the ticker symbol SER.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    ## Capital Structure and Liquidity Serina Therapeutics has a market capitalization of $22.59 million with a price-to-book ratio of 1.28, indicating that the market values the company slightly above its book value. The company's liquidity position is strong, as evidenced by a current ratio of 4.18, which is well above the industry median. However, the company reported negative net income of $6.90 million for Q1 2026, and its operating cash flow was negative at $4.57 million, suggesting ongoing operational challenges.

    ## Profitability and Returns The company's return on equity (ROE) was -39.13%, and its return on assets (ROA) was -25.27%, both significantly below the industry median for pharmaceutical companies. These negative returns indicate that the company is not generating profits from its equity or assets, which is a concern for investors.

    ## Segments and Geographic Exposure Serina Therapeutics does not disclose specific revenue segments in its filings, but it is primarily focused on research and development in the United States. The company's revenue concentration is not explicitly stated, but its operations are centered around a few key therapeutic areas, which could pose a risk if any of these areas fail to progress.

    ## Growth Trajectory The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections. The company's need for additional financing to continue operations as a going concern suggests that it may face challenges in achieving sustainable growth.

    ## Risk Factors Serina Therapeutics faces several risk factors, including the need for additional financing, the risk of dilution from future equity offerings, and the uncertainty of regulatory approval for its product candidates. The company's filings reference going-concern or substantial-doubt language, indicating potential liquidity issues. Additionally, the company's reliance on a few key therapeutic areas and the competitive nature of the pharmaceutical industry pose significant risks.

    ## Recent Events Recent events include the company's Q1 2026 filing, which highlights the need for additional financing and the potential for dilution. The company has also engaged in private placements and at-the-market offerings to raise capital, which could impact shareholder value.

    Key takeaways
    • Serina Therapeutics has a strong liquidity position with a current ratio of 4.18, but it is not generating profits, as indicated by a negative ROE of -39.13%.
    • The company's market capitalization is $22.59 million, and it is valued at a price-to-book ratio of 1.28.
    • The company's need for additional financing and the risk of dilution from future equity offerings are significant concerns for investors.
    • Serina Therapeutics is primarily focused on research and development in the United States, with no specific revenue segments disclosed.
    • The company's growth trajectory is uncertain, and it faces regulatory and competitive risks in the pharmaceutical industry.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights
    Revenue—
    Operating income—
    Net income-$6.9M
    Free cash flow-$4.6M
    EPS—
    Operating cash flow-$4.6M
    Financials
    Income statement
    Revenue—
    Gross profit—
    Operating income—
    Net income-$6.9M
    Balance sheet
    Total assets$27.3M
    Total liabilities$9.7M
    Total equity$17.6M
    Cash & equivalents$24.5M
    Long-term debt—
    Cash flow
    Operating cash flow-$4.6M
    CapEx$25.0k
    Free cash flow-$4.6M
    SBC$1.1M

    Valuation FY

    Market price
    $2,06
    Market cap
    $22.6M
    Enterprise valueⓘ
    -$1.9M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    -14.9x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    1.3x
    P / Tangible bookⓘ
    1.3x
    Tangible book
    $17.6M
    Net cashⓘ
    $24.5M
    Current ratioⓘ
    4.2
    Debt / equityⓘ
    —
    ROAⓘ
    -25.3%
    ROEⓘ
    -39.1%
    Cash conversionⓘ
    66.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    -19.1%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries3
    EX21:7b99094f6d2aEX21:7b99094f6d2aSubsidiarie97%
    EX21:9d7ed520c9deEX21:9d7ed520c9deSubsidiarie97%
    EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -1,41
    Predicted surprise
    -0,08
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-07 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-1,41
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-27,9M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-06-29

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$13,00 · Median $13,00
    Low $11,00High $15,00
    Operating income · consensus-27,9M USD
    EPS surprise
    −35,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$11,00
    Mean$13,00
    Median$13,00
    High$15,00
    Spot$2,06
    +531.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    ROE-39,1 %Below median
    D/E0,00Above median
    Cash Conv0,66Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 2 532 366 sh7 exercises · 15 grants11 insiders
    • Simon FarrellDirector · Stock Option (right to buy) → Common StockAcquired 30 500 @ $2,17grant · 2026-07-22
    • Brannan Stephen K.Director · Stock Option (right to buy) → Common StockAcquired 15 250 @ $1,98grant · 2026-06-17
    • Venkatesan JayDirector · Stock Option (right to buy) → Common StockAcquired 15 250 @ $1,98grant · 2026-06-17
    • Venkatesan JayDirector · Series A Convertible Preferred Stock → Common Stock, $0.0001 par valueDisposed 222 222 @ $5,18conversion · 2026-06-17
    • Bailey GregoryDirector · Stock Option (right to buy) → Common StockAcquired 15 250 @ $1,98grant · 2026-06-17
    • Bailey GregoryDirector · Redeemable Warrants → Common StockAcquired 3 333 333 @ $5,00grant · 2026-06-17
    • Bailey GregoryDirector · Series A Convertible Preferred Stock → Common Stock, $0.0001 par valueDisposed 1 755 555 @ $5,18conversion · 2026-06-17
    • WILSON KAREN JDirector · Stock Option (right to buy) → Common StockAcquired 15 250 @ $1,98grant · 2026-06-17
    • Marshall Richard PeterDirector · Stock Option (right to buy) → Common StockAcquired 15 250 @ $1,98grant · 2026-06-17
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockAcquired 85 558 @ $1,89grant · 2026-05-21
    • Tenjarla SriniSVP, CMC & Formulation · Stock Option (right to buy) → Common StockAcquired 85 558 @ $1,89grant · 2026-05-21
    • LEDGER STEVEN ADirector, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 380 825 @ $1,89grant · 2026-05-21
    • CURHAN GREGORY SChief Financial Officer · Stock Option (right to buy) → Common StockAcquired 123 019 @ $1,89grant · 2026-05-21
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 6 500 @ $0,06exercise · 2026-03-23
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 39 000 @ $0,06exercise · 2026-03-19
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockAcquired 69 000 @ $2,76grant · 2026-02-03
    • LEDGER STEVEN ADirector, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 230 100 @ $2,76grant · 2026-02-03
    • GILL SIMBADirector · Stock Option (right to buy) → Common StockAcquired 92 000 @ $2,76grant · 2026-02-03
    • Tenjarla SriniSVP, CMC & Formulation · Stock Option (right to buy) → Common StockAcquired 69 000 @ $2,76grant · 2026-02-03
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 6 500 @ $0,06exercise · 2026-02-02
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 6 500 @ $0,06exercise · 2026-01-28
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 2 500 @ $0,06exercise · 2026-01-22
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 2 000 @ $0,06exercise · 2026-01-21
    • Moreadith RandallChief Scientific Officer · Stock Option (right to buy) → Common StockDisposed 2 000 @ $0,06exercise · 2026-01-20

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Serina Therapeutics, Inc. company facts · 2026-05-29
    • Serina Therapeutics, Inc. 10-Q 2026-05-14 · 2026-05-29
    • Serina Therapeutics, Inc. 10-K 2026-03-25 · 2026-05-29
    • Serina Therapeutics, Inc. 10-Q 2025-11-13 · 2026-05-29
    • Serina Therapeutics, Inc. 10-Q 2025-08-11 · 2026-05-29

    Ownership & reference

    Leadership

    • Simba GillExecutive Chairman of the Board

    Insider activity

    Net selling7 buys · 7 sellsnet -$101K7 insiders · last 365d
    • Brannan Stephen K.Director · Common StockBought 1 000 @ $2,03$2K · 2026-07-07
    • Bailey GregoryDirector · Common StockOther 6 666 667 @ $2,25$15,0M · 2026-06-17
    • Venkatesan JayDirector · Common StockOther 224 152 @ $2,25$504K · 2026-06-17
    • Bailey GregoryDirector · Common StockOther 1 770 805 @ $2,25$4,0M · 2026-06-17
    • WILSON KAREN JDirector · Common StockBought 5 000 @ $1,77$9K · 2026-06-12
    • WILSON KAREN JDirector · Common StockBought 5 100 @ $1,75$9K · 2026-06-11
    • LEDGER STEVEN ADirector, Chief Executive Officer · Common StockOther 10 100 @ $1,93$19K · 2026-05-26
    • Venkatesan JayDirector · Common StockBought 589 @ $1,78$1K · 2026-05-22
    • WILSON KAREN JDirector · Common StockBought 10 000 @ $1,93$19K · 2026-05-22
    • WILSON KAREN JDirector · Common StockBought 10 000 @ $1,77$18K · 2026-05-21
    • Marshall Richard PeterDirector · Common StockBought 12 183 @ $1,65$20K · 2026-05-19
    • Venkatesan JayDirector · Common StockOther 7 553 @ $1,94$15K · 2026-03-31
    • Bailey GregoryDirector · Common StockOther 59 667 @ $1,94$116K · 2026-03-31
    • Moreadith RandallChief Scientific Officer · Common StockOther 6 500 @ $0,06$390 · 2026-03-23
    • Moreadith RandallChief Scientific Officer · Common StockSold 6 500 @ $2,86$19K · 2026-03-23
    • Moreadith RandallChief Scientific Officer · Common StockOther 39 000 @ $0,06$2K · 2026-03-19
    • Moreadith RandallChief Scientific Officer · Common StockSold 39 000 @ $2,50$98K · 2026-03-19
    • Moreadith RandallChief Scientific Officer · Common StockOther 6 500 @ $0,06$390 · 2026-02-02
    • Moreadith RandallChief Scientific Officer · Common StockSold 6 500 @ $3,03$20K · 2026-02-02
    • Moreadith RandallChief Scientific Officer · Common StockOther 6 500 @ $0,06$390 · 2026-01-28
    • Moreadith RandallChief Scientific Officer · Common StockSold 6 500 @ $3,57$23K · 2026-01-28
    • Moreadith RandallChief Scientific Officer · Common StockOther 2 500 @ $0,06$150 · 2026-01-22
    • Moreadith RandallChief Scientific Officer · Common StockSold 2 500 @ $2,95$7K · 2026-01-22
    • Moreadith RandallChief Scientific Officer · Common StockOther 2 000 @ $0,06$120 · 2026-01-21
    • Moreadith RandallChief Scientific Officer · Common StockSold 2 000 @ $3,00$6K · 2026-01-21

    Short positioning

    284.5Kshares short-0.3% vs prior
    5.23days to cover
    24.3%short of daily vol
    4.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SERCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,08Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.
    Relationship graph
    SEREX21:7b9EX21:9d7EX21:d30Pharmaceutical
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 168.2%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -105.8%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 75.9%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 132.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -40.9%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -26.5%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -26.5%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 12.4%Derived (calculated)
    • Net margin (FY 2025-12-31): -14,755.4%Derived (calculated)
    • Return on equity (FY 2025-12-31): 51,843.2%Derived (calculated)
    • Return on assets (FY 2025-12-31): -276.0%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.71xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): -188.86xDerived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -4.8%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -72.2%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -16.8%Derived (calculated)
    • Total assets (annual): USD 6.95MSEC XBRL filing
    • Total liabilities (annual): USD 6.99MSEC XBRL filing
    • Pre-tax income (annual): USD -19.2MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
    • R&D expense (annual): USD 13.15MSEC XBRL filing
    • Shareholders' equity (annual): USD -37KSEC XBRL filing
    • Cash & equivalents (annual): USD 3.06MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-22INSIDERSimon Farrell acquired 30.5k sh Stock Option (right to buy) — Director
    2026-07-07INSIDERBrannan Stephen K. bought 1.0k sh — Director ~$2k
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-17 00:00 UTCINSIDER13 insider transactions — 2026-06 · net buy $19.5M 8 derivative
    2026-06-17INSIDERBailey Gregory transacted 6.67M sh — Director ~$15.00M
    2026-06-17INSIDERVenkatesan Jay transacted 224.2k sh — Director ~$504k
    2026-06-17INSIDERBailey Gregory transacted 1.77M sh — Director ~$3.98M
    2026-06-17INSIDERVenkatesan Jay disposed of 96.5k sh Series A Convertible Preferred Stock — Director
    2026-06-17INSIDERBailey Gregory acquired 15.2k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERVenkatesan Jay acquired 15.2k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERBailey Gregory acquired 3.33M sh Redeemable Warrants — Director
    2026-06-17INSIDERBailey Gregory disposed of 762.5k sh Series A Convertible Preferred Stock — Director
    2026-06-17INSIDERBrannan Stephen K. acquired 15.2k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERWILSON KAREN J acquired 15.2k sh Stock Option (right to buy) — Director
    2026-06-17INSIDERMarshall Richard Peter acquired 15.2k sh Stock Option (right to buy) — Director
    2026-06-12INSIDERWILSON KAREN J bought 5.0k sh — Director ~$9k
    2026-06-11INSIDERWILSON KAREN J bought 5.1k sh — Director ~$9k
    2026-05-26 00:00 UTCINSIDER9 insider transactions — 2026-05 4 derivative
    2026-05-26INSIDERLEDGER STEVEN A transacted 10.1k sh — Director, Chief Executive Officer ~$19k
    2026-05-22INSIDERVenkatesan Jay bought 589 sh — Director ~$1k
    2026-05-22INSIDERWILSON KAREN J bought 10.0k sh — Director ~$19k
    2026-05-21INSIDERWILSON KAREN J bought 10.0k sh — Director ~$18k
    2026-05-21INSIDERTenjarla Srini acquired 85.6k sh Stock Option (right to buy) — SVP, CMC & Formulation
    2026-05-21INSIDERLEDGER STEVEN A acquired 380.8k sh Stock Option (right to buy) — Director, Chief Executive Officer
    2026-05-21INSIDERCURHAN GREGORY S acquired 123.0k sh Stock Option (right to buy) — Chief Financial Officer
    2026-05-21INSIDERMoreadith Randall acquired 85.6k sh Stock Option (right to buy) — Chief Scientific Officer
    2026-05-19INSIDERMarshall Richard Peter bought 12.2k sh — Director ~$20k
    2026-05-14FILING8-K filing →
    2026-05-14FILING10-Q filing →
    2026-04-27FILINGDEF 14A filing →
    2026-04-21FILING8-K filing →
    2026-03-31 00:00 UTCINSIDER8 insider transactions — 2026-03 · $249k gross 2 derivative
    2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -6.9M
    2026-03-31INSIDERVenkatesan Jay transacted 7.6k sh — Director ~$15k
    2026-03-31INSIDERBailey Gregory transacted 59.7k sh — Director ~$116k
    2026-03-25FILING8-K filing →
    2026-03-25FILING10-K filing →
    2026-03-23FILING8-K filing →
    2026-03-23INSIDERMoreadith Randall transacted 6.5k sh — Chief Scientific Officer ~$0k
    Showing the 40 most recent of 65 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage